CY1109316T1 - Συνδυαστικη αγωγη για πολλαπλη σκληρυνση - Google Patents
Συνδυαστικη αγωγη για πολλαπλη σκληρυνσηInfo
- Publication number
- CY1109316T1 CY1109316T1 CY20091100869T CY091100869T CY1109316T1 CY 1109316 T1 CY1109316 T1 CY 1109316T1 CY 20091100869 T CY20091100869 T CY 20091100869T CY 091100869 T CY091100869 T CY 091100869T CY 1109316 T1 CY1109316 T1 CY 1109316T1
- Authority
- CY
- Cyprus
- Prior art keywords
- cda
- alpha
- agent
- integrin antibody
- combination
- Prior art date
Links
- 230000001149 cognitive effect Effects 0.000 title 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 abstract 3
- 102000006495 integrins Human genes 0.000 abstract 2
- 108010044426 integrins Proteins 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 230000002411 adverse Effects 0.000 abstract 1
- 238000011284 combination treatment Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000002889 endothelial cell Anatomy 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 210000001616 monocyte Anatomy 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Electrotherapy Devices (AREA)
- Transplanting Machines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63867404P | 2004-12-22 | 2004-12-22 | |
| EP04106910 | 2004-12-22 | ||
| EP05823965A EP1835922B1 (en) | 2004-12-22 | 2005-12-20 | Combination treatment for multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1109316T1 true CY1109316T1 (el) | 2014-07-02 |
Family
ID=35789196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20091100869T CY1109316T1 (el) | 2004-12-22 | 2009-08-12 | Συνδυαστικη αγωγη για πολλαπλη σκληρυνση |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20100129353A1 (enExample) |
| EP (1) | EP1835922B1 (enExample) |
| JP (1) | JP2008524310A (enExample) |
| AT (1) | ATE431740T1 (enExample) |
| AU (1) | AU2005318183B2 (enExample) |
| CA (1) | CA2590471A1 (enExample) |
| CY (1) | CY1109316T1 (enExample) |
| DE (1) | DE602005014570D1 (enExample) |
| DK (1) | DK1835922T3 (enExample) |
| ES (1) | ES2325552T3 (enExample) |
| HR (1) | HRP20090417T1 (enExample) |
| IL (1) | IL183924A (enExample) |
| NO (1) | NO20073635L (enExample) |
| PL (1) | PL1835922T3 (enExample) |
| PT (1) | PT1835922E (enExample) |
| SI (1) | SI1835922T1 (enExample) |
| WO (1) | WO2006067134A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024282654A1 (en) | 2023-05-30 | 2025-12-04 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2521565B1 (fr) * | 1982-02-17 | 1985-07-05 | Dior Sa Parfums Christian | Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees |
| FR2534487B1 (fr) * | 1982-10-15 | 1988-06-10 | Dior Christian Parfums | Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede |
| US5310732A (en) * | 1986-02-03 | 1994-05-10 | The Scripps Research Institute | 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis |
| US5077211A (en) * | 1988-07-06 | 1991-12-31 | Applied Genetics, Inc. | Purification and administration of dna repair enzymes |
| US6172197B1 (en) * | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9206318D0 (en) * | 1992-03-24 | 1992-05-06 | Cambridge Antibody Tech | Binding substances |
| GB9015198D0 (en) * | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DE69230142T2 (de) * | 1991-05-15 | 2000-03-09 | Cambridge Antibody Technology Ltd. | Verfahren zur herstellung von spezifischen bindungspaargliedern |
| US6225447B1 (en) * | 1991-05-15 | 2001-05-01 | Cambridge Antibody Technology Ltd. | Methods for producing members of specific binding pairs |
| US5565332A (en) * | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5885793A (en) * | 1991-12-02 | 1999-03-23 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
| US5872215A (en) * | 1991-12-02 | 1999-02-16 | Medical Research Council | Specific binding members, materials and methods |
| US5208327A (en) * | 1991-12-18 | 1993-05-04 | Ortho Pharmaceutical Corporation | Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine |
| US5733743A (en) * | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| AU690528B2 (en) * | 1992-12-04 | 1998-04-30 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| US5840299A (en) * | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| US6001809A (en) * | 1994-07-11 | 1999-12-14 | Elan Pharmaceuticals, Inc. | Inhibitors of leukocyte adhesion |
| GB9712818D0 (en) * | 1996-07-08 | 1997-08-20 | Cambridge Antibody Tech | Labelling and selection of specific binding molecules |
| US6194395B1 (en) * | 1999-02-25 | 2001-02-27 | Orthro-Mcneil Pharmaceutical, Inc. | Cyclodextrin cladribine formulations |
| EP1485127B1 (en) * | 2002-02-25 | 2011-06-08 | Elan Pharmaceuticals, Inc. | Administration of agents for the treatment of inflammation |
| KR20060011943A (ko) * | 2003-03-28 | 2006-02-06 | 아이박스 코포레이션 | 향상된 경구 및 경점막 수송용 클라드리빈 제형 |
-
2005
- 2005-12-20 DE DE602005014570T patent/DE602005014570D1/de not_active Expired - Lifetime
- 2005-12-20 HR HR20090417T patent/HRP20090417T1/xx unknown
- 2005-12-20 PL PL05823965T patent/PL1835922T3/pl unknown
- 2005-12-20 EP EP05823965A patent/EP1835922B1/en not_active Expired - Lifetime
- 2005-12-20 AT AT05823965T patent/ATE431740T1/de active
- 2005-12-20 WO PCT/EP2005/056943 patent/WO2006067134A1/en not_active Ceased
- 2005-12-20 JP JP2007547483A patent/JP2008524310A/ja not_active Withdrawn
- 2005-12-20 AU AU2005318183A patent/AU2005318183B2/en not_active Ceased
- 2005-12-20 CA CA002590471A patent/CA2590471A1/en not_active Abandoned
- 2005-12-20 DK DK05823965T patent/DK1835922T3/da active
- 2005-12-20 SI SI200530731T patent/SI1835922T1/sl unknown
- 2005-12-20 US US11/722,487 patent/US20100129353A1/en not_active Abandoned
- 2005-12-20 ES ES05823965T patent/ES2325552T3/es not_active Expired - Lifetime
- 2005-12-20 PT PT05823965T patent/PT1835922E/pt unknown
-
2007
- 2007-06-14 IL IL183924A patent/IL183924A/en not_active IP Right Cessation
- 2007-07-13 NO NO20073635A patent/NO20073635L/no not_active Application Discontinuation
-
2009
- 2009-08-12 CY CY20091100869T patent/CY1109316T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI1835922T1 (sl) | 2009-10-31 |
| PL1835922T3 (pl) | 2009-10-30 |
| ES2325552T3 (es) | 2009-09-08 |
| NO20073635L (no) | 2007-09-24 |
| ATE431740T1 (de) | 2009-06-15 |
| PT1835922E (pt) | 2009-07-08 |
| JP2008524310A (ja) | 2008-07-10 |
| CA2590471A1 (en) | 2006-06-29 |
| DE602005014570D1 (enExample) | 2009-07-02 |
| EP1835922A1 (en) | 2007-09-26 |
| AU2005318183A1 (en) | 2006-06-29 |
| IL183924A (en) | 2010-11-30 |
| EP1835922B1 (en) | 2009-05-20 |
| IL183924A0 (en) | 2007-10-31 |
| DK1835922T3 (da) | 2009-08-03 |
| US20100129353A1 (en) | 2010-05-27 |
| WO2006067134A1 (en) | 2006-06-29 |
| AU2005318183B2 (en) | 2011-03-31 |
| HRP20090417T1 (hr) | 2009-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR2869231B1 (fr) | Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine | |
| GB2506085A (en) | Combination treatment (eg with ABT-072 or ABT-333) of DAAS for use in treating HCV | |
| ITMI20041550A1 (it) | Uso di batteri probiotici per la preparazione di composizioni topiche per la protezione dell'epidermide | |
| BR0308090A (pt) | conjugados de agentes citotóxicos ou terapêuticos e peptìdios biologicamente ativos | |
| UA101309C2 (ru) | Антагонисты активина-actrii и их применение для повышения уровня эритроцитов | |
| NO332893B1 (no) | Anvendelse av antistoff for fremstilling av medikament til anvendelse ved CVP-kjemoterapi | |
| DE60318192D1 (de) | Verwendung von a2a adenosin rezeptor agonisten und anti-pathogene mittel enthaltenden kombinationen zur behandlung von entzündungskrankheiten | |
| CO5700791A2 (es) | Metodos para tratar enfermedades relacionadas con interleukin-6 | |
| MXPA05013642A (es) | Composicion de un antagonista de vegf y un agente antiproliferativo y su uso para el tratamiento de cancer. | |
| MX2009003122A (es) | Inhibidores de tirosina cinasa de bruton. | |
| DE60114406D1 (de) | Wirkstoffabgabesysteme zur behandlung von gefässerkrankungen | |
| BRPI0516531A (pt) | imunoterapia de distúrbios auto-imunes | |
| NO20052362L (no) | Fremgangsmater for administrering av dalbavancin for behandling av bakterielle infeksjoner | |
| BRPI0509140A (pt) | processos para o tratamento de infecção por hiv | |
| PH12021550965A1 (en) | Combination therapy for treatment of hematological diseases | |
| DE60036915D1 (de) | Verwendung von hyaluronan zur herstellung eines medikaments zur erhöhung der wirksamkeit von zytotoxischen arzneimitteln | |
| NO20064287L (no) | Dalbavancin-materialer for behandling av bakterielle infeksjoner | |
| DE60108489D1 (de) | Kombinationstherapien mit gefässschädigender aktivität | |
| FR2834459B1 (fr) | Agent microbicide et composition de traitement cosmetique le contenant | |
| ATE466595T1 (de) | Verbindungen und methoden für das downregulating der effekte von tgf-beta | |
| ATE423114T1 (de) | Aminocyclopropancarbonsäureamidderivate als bradykininantagonisten | |
| BR0310061A (pt) | Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições | |
| CY1113488T1 (el) | Ενα φαρμακο για την δυο βαθμιδων περιεγχειρητικη θεραπεια συμπαγων ογκων δια ραδιοανοσοθεραπειας | |
| BR0317539A (pt) | Métodos e composições para o tratamento de infecções por vìrus da herpes usando inibidores seletivos da ou ciclooxigenase-2 ou inibidores da ciclooxigenase-2 em combinação com agentes antivirais | |
| CY1109316T1 (el) | Συνδυαστικη αγωγη για πολλαπλη σκληρυνση |